Virtual dialogue to discuss HPV-based cervical cancer screening
The Union for International Cancer Control and WHO will host a session on 12 November to explore translating new guidance into practice using experiences from Malawi and Mongolia.

The Union for International Cancer Control (UICC) and the World Health Organization (WHO) will host a virtual dialogue titled 'From guidance to practice: advancing HPV-based cervical cancer screening' on Thursday 12 November. The session will run from 11:00-12:00 CET.
WHO experts will present the latest guidance and discuss how recommendations on HPV genotyping and program implementation can support countries in strengthening screening strategies, risk-based management, and sustainable scale-up. The dialogue will draw on experiences from Mongolia and Malawi to explore how new WHO guidance can be translated into practice.
Speakers for the event include Dr Mariluz Hernandez Viadel from the WHO, Dr Tsetsegsaikhan Batmunkh from the Ministry of Health and National Cancer Council of Mongolia, Maud Mwakasungula from the Women’s Coalition Against Cancer (WOCACA) in Malawi, and Timothy Tchereni H. from the Clinton Health Access Initiative, Inc. (CHAI) in Malawi. Sabrina Zucchello from the UICC will moderate the session.
The guidance reaffirms HPV DNA testing as the preferred primary screening tool over traditional Pap smears or Visual Inspection with Acetic Acid because of its higher sensitivity and negative predictive value. The reliability of molecular testing allows health systems to safely extend screening intervals to five to ten years for the general population.
The guidance provides operational strategies for health system planning, supply chain stability, laboratory quality assurance, and workforce training. The WHO also emphasizes self-collected vaginal sampling as a critical delivery mechanism to overcome cultural and access barriers.
The guidance establishes tailored clinical pathways for women living with HIV, who face a higher risk of persistent HPV infection and rapid disease progression. It also includes a categorization of testing capacity to assist program managers in structuring risk-based triage and clinical management.
Key facts
- The virtual dialogue on HPV-based cervical cancer screening is scheduled for Thursday 12 November from 11:00-12:00 CET.
- HPV DNA testing is the preferred primary screening tool over Pap smears or Visual Inspection with Acetic Acid.
- Molecular testing allows health systems to extend screening intervals to five to ten years for the general population.
Perspectives
Neutral
The UICC and WHO will host a virtual dialogue on 12 November to discuss implementing new WHO guidance on HPV-based cervical cancer screening.
Positive
The guidance provides actionable operational strategies for scaling up screening infrastructure, including supply chain stability and workforce training.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.